Consistently, our immune profiling analyses using both CIBERSORT and xCell demonstrated that high-risk AML patients exhibit a higher proportion of M2 macrophages, further reinforcing the clinical relevance of ELANE in modulating the tumor microenvironment. The gene discussed is ELANE; the disease is acute myeloid leukemia.